Jagsonpal Pharmaceuticals delivered a strong finish to FY26, reporting a sharp 31% jump in quarterly profit and unveiling shareholder rewards including a Rs. 40 crore buyback and a 200% dividend payout.
The drugmaker posted Q4 revenue of Rs. 642 million, up 10% year-on-year, while profit after tax (PAT) climbed to Rs. 88 million. For the full year, revenue rose 7% to Rs. 2,872 million, with PAT increasing 19% to Rs. 446 million, reflecting steady operational momentum.
Margins held firm despite expansion, with full-year EBITDA at Rs. 609 million and a margin of 21.2%. The company also strengthened its balance sheet, ending the year with a cash position of Rs. 1,907 million—an increase of Rs. 451 million.
In a clear signal of confidence, the board approved a buyback of up to 16 lakh shares at Rs. 250 per share, aggregating Rs. 40 crore. Promoters will not participate. The move is expected to lift return ratios, with ROCE projected to rise to 25.7% and ROE to 18.9%.
Additionally, the company proposed a 200% dividend, including a 75% special dividend, translating into a cash outlay of about Rs. 262 million.
Performance was powered by strong execution and demand traction, particularly from its top brands, which contribute nearly 58% of revenue. The company also outpaced industry growth trends during the quarter.
Commenting on the results, Manish Gupta, Managing Director and CEO, said: "Our business regained traction in Q4 with growth of 10% on strength of sharper strategic execution. This is reflecting in our industry outpacing performance, with Pharmarack reflecting a 12.2% growth for Jagsonpal as compared to IPM growth of 8.6%.
Our ‘Top 10’ brands which account for ~58% of revenues continue to drive performance. Our yearly revenues grew 7% while our operating net profit grew 19% in the same period, with the year closing with a healthy cash position of Rs. 191 crores."
"The Board has recommended a dividend of 200% (including a special dividend of 75%) for FY26. These shareholders-centric actions are reflective of our confidence in growth momentum of business in FY27 and beyond, with continued strong cash generation and improving ROCE/ROE."
